0W10 Stock Overview
MagForce AG develops advanced nanomedicine for cancer therapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MagForce AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.006 |
| 52 Week High | €0.006 |
| 52 Week Low | €0.001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 200.00% |
| 3 Year Change | -99.89% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0W10 | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 2.3% |
| 1Y | 200.0% | -9.3% | 0.6% |
Return vs Industry: 0W10 exceeded the UK Medical Equipment industry which returned -3.9% over the past year.
Return vs Market: 0W10 exceeded the UK Market which returned -0.6% over the past year.
Price Volatility
| 0W10 volatility | |
|---|---|
| 0W10 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0W10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0W10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 33 | Ben Lipps | www.magforce.de/ |
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of brain tumors; NanoPlan, a software that supports the attending physician in preparing the ideal treatment plan for the NanoTherm therapy; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce AG Fundamentals Summary
| 0W10 fundamental statistics | |
|---|---|
| Market cap | €6.11k |
| Earnings (TTM) | -€10.57m |
| Revenue (TTM) | €1.08m |
0.0x
P/S Ratio0.0x
P/E RatioIs 0W10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0W10 income statement (TTM) | |
|---|---|
| Revenue | €1.08m |
| Cost of Revenue | €918.75k |
| Gross Profit | €158.39k |
| Other Expenses | €10.73m |
| Earnings | -€10.57m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 0W10 perform over the long term?
See historical performance and comparison